Kiniksa Pharmaceuticals International, plc (KNSA) scores 64 out of 100 on boothcheck's 11-model valuation framework. Verdict: Fair The estimated fair value is 57.3, representing a 19% margin of safety. Quantitative score: 57/100. Qualitative score: 90/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.